1.
Korkmaz T, Seber S, Basaran G. Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; in the light of completed trials. Crit Rev Oncol Hematol. 2016;98:180–8.
CrossRefPubMed
2.
Markman M. Maintenance chemotherapy in the management of epithelial ovarian cancer. Cancer Metastasis Rev. 2015;34(1):11–7.
CrossRefPubMed
3.
Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a southwest oncology group and gynecologic oncology group trial. J Clin Oncol. 2003;21(13):2460–5.
CrossRefPubMed
4.
Markman M, Liu PY, Moon J, Monk BJ, Copeland L, Wilczynski S, et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a southwest oncology group and gynecologic oncology group phase 3 trial. Gynecol Oncol. 2009;114(2):195–8.
CrossRefPubMedPubMedCentral
5.
Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, et al. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. J Clin Oncol. 2009;27(28):4642–8.
CrossRefPubMed
6.
Copeland LJ, Brady MF, Burger RA, Rodgers WH, Huang H, Cella D, et al. A phase III trial of maintenance therapy in women with advanced ovarian/fallopian tube/peritoneal cancer (O/PC/FT ) after a complete clinical response (CCR) to first-line therapy: an NRG oncology study [late-breaking abstract]. National Harbor, Maryland: SGO Annual Meeting on Women's Cancer; 2017.
7.
Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83.
CrossRefPubMed
8.
Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96.
CrossRefPubMed
9.
Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–36.
CrossRefPubMedPubMedCentral
10.
Burger RA, Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, et al. Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2014;32(12):1210–7.
CrossRefPubMedPubMedCentral
11.
Ray-Coquard IL, Harter P, Martin AG, Cropet C, Pignata S, Fujiwara K, et al. PAOLA-1: An ENGOT/GCIG phase III trial of olaparib versus placebo combined with bevacizumab as maintenance treatment in patients with advanced ovarian cancer following first-line platinum-based chemotherapy plus bevacizumab [abstract and poster presented at 2017 ASCO Annual Meeting]. J Clin Oncol. 2017;35(suppl):abstr TPS5605.
12.
Pujade-Lauraine E, Combe P. Recurrent ovarian cancer. Ann Oncol. 2016;27(Suppl 1):i63–5.
CrossRefPubMed
14.
Alberts DS, Liu PY, Wilczynski SP, Clouser MC, Lopez AM, Michelin DP, et al. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (southwest oncology group protocol S0200). Gynecol Oncol. 2008;108(1):90–4.
CrossRefPubMed
15.
Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 Trial. Lancet. 2003;361(9375):2099–106.
CrossRefPubMed
16.
Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699–707.
CrossRefPubMed
17.
Raja FA, Counsell N, Colombo N, Pfisterer J, du Bois A, Parmar MK, et al. Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data. Ann Oncol. 2013;24(12):3028–34.
CrossRefPubMed
18.
Bruchim I, Jarchowsky-Dolberg O, Fishman A. Advanced (>second) line chemotherapy in the treatment of patients with recurrent epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2013;166(1):94–8.
CrossRefPubMed
19.
Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. Ann Oncol. 2012;23(10):2605–12.
CrossRefPubMed
20.
Penson RT, Dignan F, Seiden MV, Lee H, Gallagher CJ, Matulonis UA, et al. Attitudes to chemotherapy in patients with ovarian cancer. Gynecol Oncol. 2004;94(2):427–35.
CrossRefPubMed
21.
Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H, et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007;25(33):5180–6.
CrossRefPubMed
22.
Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol. 2007;25(33):5165–71.
CrossRefPubMed
23.
Monk BJ, Han E, Josephs-Cowan CA, Pugmire G, Burger RA. Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. Gynecol Oncol. 2006;102(2):140–4.
CrossRefPubMed
24.
Pietzner K, Richter R, Chekerov R, Erol E, Oskay-Ozcelik G, Lichtenegger W, et al. Bevacizumab in heavily pre-treated and platinum resistant ovarian cancer: a retrospective study of the north-eastern German Society of Gynaecologic Oncology (NOGGO) ovarian cancer study group. Anticancer Res. 2011;31(8):2679–82.
PubMed
25.
Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–8.
CrossRefPubMed
26.
Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–45.
CrossRefPubMedPubMedCentral
27.
Aghajanian C, Goff B, Nycum LR, Wang YV, Husain A, Blank SV. Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol. 2015;139(1):10–6.
CrossRefPubMedPubMedCentral
28.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, et al. Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG oncology/gynecologic oncology group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(6):779–91.
CrossRefPubMed
29.
Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmana J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol. 2015;33(3):244–50.
CrossRefPubMed
30.
Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016;140(2):199–203.
CrossRefPubMed
31.
Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12(9):852–61.
CrossRefPubMed
32.
Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 2017;18(1):75–87.
CrossRefPubMed
33.
Avastin (bevacizumab) [prescribing information]. South San Francisco: Genentech, Inc.; 2016.
34.
Clovis Oncology Inc. Rubraca (rucaparib) tablets [prescribing information]. Boulder, CO: Clovis Oncology, Inc.; 2016.
35.
AstraZeneca Pharmaceuticals LP. Lynparza (olaparib) capsules [prescribing information]. AstraZeneca Pharmaceuticals LP: Wilmington, DE; 2017.
36.
Tesaro Inc. Zejula (niraparib) capsules [prescribing information]. Waltham, MA: Tesaro, Inc.; 2017.
37.
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–92.
CrossRefPubMed
38.
Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–64.
CrossRefPubMed
39.
Pujade-Lauraine E, Ledermann JA, Penson RT, Oza AM, Korach J, Huzarski T, et al. Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: results from the phase III SOLO-2 study (abstract and presentation slides). National Harbor, Maryland: SGO Annual Meeting on Women's Cancer; 2017.
40.
Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852–61.
CrossRefPubMed
41.
Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016;17(11):1579–89.
CrossRefPubMed
42.
Friedlander M, Gebski V, Gibbs E, Bloomfield R, Hilpert F, Wenzel LB, et al. Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO-2 phase III trial [abstract presented at 2017 ASCO Annual Meeting]. J Clin Oncol. 2017;35(suppl):abstr 5507.
43.
Mirza MR, Monk BJ, Gil-Martin M, Gilbert L, Canzler U, Follana P, et al. Efficacy of niraparib on progression-free survival (PFS) in patients (pts) with recurrent ovarian cancer (OC) with partial response (PR) to the last platinum-based chemotherapy [abstract and poster presented at 2017 ASCO Annual Meeting]. J Clin Oncol. 2017;35(suppl):abstr 5517.
44.
Del Campo JM, Mirza MR, Berek JS, Provencher DM, Emons G, Fabbro M, et al. The successful phase 3 niraparib ENGOT-OV16/NOVA trial included a substantial number of patients with platinum resistant ovarian cancer (OC) [abstract and poster presented at 2017 ASCO Annual Meeting]. J Clin Oncol. 2017;35(suppl):abstr 5560.
47.
Ramus SJ, Gayther SA. The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol. 2009;3(2):138–50.
CrossRefPubMedPubMedCentral
48.
Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD 2nd, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol. 2010;28(22):3570–6.
CrossRefPubMedPubMedCentral
49.
Chetrit A, Hirsh-Yechezkel G, Ben-David Y, Lubin F, Friedman E, Sadetzki S. Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer. J Clin Oncol. 2008;26(1):20–5.
CrossRefPubMed
50.
Alsop K, Fereday S, Meldrum C. deFazio a, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. J Clin Oncol. 2012;30(21):2654–63.
CrossRefPubMedPubMedCentral
51.
Pothuri B. BRCA1- and BRCA2-related mutations: therapeutic implications in ovarian cancer. Ann Oncol. 2013;24(Suppl 8):viii22-viii7.
53.
Cadoo KA, Aghajanian C, Fraser C, Milner A, Kolvenbag G. A phase 2 study to assess olaparib by homologous recombination deficiency status in patients with platinum-sensitive, relapsed, ovarian, fallopian tube, or primary peritoneal cancer [abstract and poster presented at 2017 ASCO Annual Meeting]. J Clin Oncol. 2017;35(suppl):abstr TPS5606.
54.
Liu JF, Barry WT, Birrer MJ, Lee JM, Buckanovich RJ, Fleming GF, et al. Overall survival and updated progression-free survival results from a randomized phase 2 trial comparing the combination of olaparib and cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer [abstract and poster presented at 2017 ASCO Annual Meeting]. J Clin Oncol. 2017;35(suppl):abstr 5535.
60.
Leffers N, Daemen T, Boezen HM, Melief KJ, Nijman HW. Vaccine-based clinical trials in ovarian cancer. Expert Rev Vaccines. 2011;10(6):775–84.
CrossRefPubMed
61.
Liao JB, Disis ML. Therapeutic vaccines for ovarian cancer. Gynecol Oncol. 2013;130(3):667–73.
CrossRefPubMed
63.
United States Food and Drug Administration. Guidance for Industry: Expedited Programs for Serious Conditions – Drugs and Biologics. May 2014 Procedural. https://wwwfdagov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm358301pdf Accessed: 12 May 2017.
64.
Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19(14):3312–22.
CrossRefPubMed
65.
Gordon AN, Tonda M, Sun S, Rackoff W. Doxil study investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol. 2004;95(1):1–8.
CrossRefPubMed
66.
Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377(1):62–70.
CrossRefPubMed